‌Remote ischemic preconditioning (RIPC) shows promise in protecting the heart during valve replacement surgery. Findings from a meta-analysis of nine studies including 1,269 patients, presented at ESC 2025, reveal that RIPC significantly lowers myocardial injury markers. Patients receiving RIPC exhibited reduced levels of CK-MB and troponin I, suggesting effective cardiac protection during surgery.

Additionally, RIPC shortened the duration of invasive ventilation, highlighting a potential cardiopulmonary benefit. Despite these biochemical improvements, the analysis found no significant reductions in acute kidney injury, ICU stay, or overall hospital length of stay.

These findings suggest that RIPC can provide measurable myocardial protection in valve surgery, yet its influence on broader clinical outcomes remains limited. The study underscores the need for further research to identify patient populations that may derive the greatest clinical benefit and to explore protocols that might translate myocardial protection into improved post-operative recovery.